BioTuesdays

Category - News

Sophiris Bio Logo
Markets

Maxim ups Sophiris Bio PT to $8

Maxim Group raised its price target for Sophiris Bio (NASDAQ:SPHS) to $8 from $5, factoring in topsalysin data in prostate cancer at the end of the second quarter. The stock was quoted at $3.55 in afternoon trading on...

May 15, 2018
Zymeworks Logo
Markets

Ladenburg starts Zymeworks at buy; PT $25

Ladenburg Thalmann initiated coverage of Zymeworks (NYSE:ZYME) with a “buy” rating and $25 price target. The stock closed at $15.84 on May 14. Zymeworks is developing bispecific/multifunctional biotherapeutics initially...

May 15, 2018
Coherus BioSciences Logo
Markets

Maxim ups Coherus Biosciences PT to $22

Maxim Group raised its price target for Coherus Biosciences (NASDAQ:CHRS) to $22 from $18 after the FDA has accepted for review the recently resubmitted BLA for CHS-1701 (Neulasta biosimilar). This is a Type I response...

May 14, 2018
IntelGenx Logo
Developments

IntelGenx settles Suboxone patent litigation

All patent litigation between IntelGenx (TSXV:IGX; OTCQX:IGXT), Par Pharmaceutical, Indivior and Indivior UK, and Aquestive Therapeutics (formerly MonoSol Rx) related to Suboxone film has been settled. The accord...

May 14, 2018
Tandem Diabetes Care
Markets

Piper ups Tandem Diabetes to OW; PT $13

Piper Jaffray upgraded Tandem Diabetes (NASDAQ:TNDM) to “overweight” from “neutral” and raised its price target to $13 from $8 after hosting meetings with the company’s CEO and CFO. The stock closed at $8.90 on April 11...

May 14, 2018
3D Signatures
Developments

3DS strengthens IP with new patents

3D Signa­­­­­­tures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) recently received a patent from the Canadian Intellectual Property office, which protects the company’s IP in the area of cognitive diseases in general and...

May 10, 2018